Skip to content

ScaiDigest July 2023

ScaiDigest July 2023

ScaiDigest July 2023

ScaiDigest July 2023

We are excited to announce the launch of ScaiDigest, a regular scientific post that delves into the latest research papers in our field. 

In our inaugural edition, Diana Stoycheva, Principal Expert Scientist, shared interesting insights on the application of single-cell and multi-omics technologies to CAR T cell therapy.

“Application of Single-cell and multi-omics technologies in CAR T cell therapy

Chimeric antigen receptor (CAR) T cell therapy approaches have shown great potential to introduce a significant change to the treatment of cancer. However, the therapy’s full potential is yet to be unlocked as the scientific community is still learning about the intricacies of the mechanism of action, clinical implications and in vivo activity.


Single-cell and multi-omics approaches could be the key to unlocking the full potential of CAR T therapy and optimizing the therapy’s safety and efficacy as the approaches become more widely used. The full extent of using such approaches is highlighted in the works of Barboy et al. and Yang, Chen and Han.


The utilization of multi-omics data at single-cell resolution provides scientists with an immense amount of data which could be applied in different ways such as enhancing the efficacy of CAR T cell therapy, determining optimal CAR targets and minimizing the CAR T cell-related toxicities. Furthermore, the use of computational approaches, like machine learning and artificial intelligence, has been highlighted as the method of expediting the integration of multi-omics data in both discovery and clinical evaluation.”  

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212274/

https://aacrjournals.org/cancerdiscovery/article-abstract/13/7/1546/727638/In-Synergy-Optimizing-CAR-T-Development-and

Stay tuned for more insightful posts in ScaiDigest, where we will continue to share  scientific advancements which excite us and their potential impact on healthcare.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Read more

Recent News

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...

Read more

Recent News

Scailyte at BIO International Convention 2024

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where busin...

Read more

Recent News

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News

Precision Med TRI-CON 2024

Join us for our presentation on "Enabling Precision Medicine by Combining Single-Cell Multi-Omics Da...

Read more

Recent News

Inside Scailyte - Episode 9: Meet Shaoline Sheppard

In the latest episode of "Inside Scailyte," we're thrilled to introduce you to Shaoline Sheppard, ou...

Read more

Recent News

NextGen Omics US 2024

Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...

Read more

Recent News

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...

Read more

Recent News

01 /04

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Read more

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...

Read more

Recent News

02 /04

Scailyte at BIO International Convention 2024

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where busin...

Read more

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News

03 /04

Precision Med TRI-CON 2024

Join us for our presentation on "Enabling Precision Medicine by Combining Single-Cell Multi-Omics Da...

Read more

Inside Scailyte - Episode 9: Meet Shaoline Sheppard

In the latest episode of "Inside Scailyte," we're thrilled to introduce you to Shaoline Sheppard, ou...

Read more

Recent News

04 /04

NextGen Omics US 2024

Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...

Read more

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...

Read more

Recent News